MFN Partners’s Cyclerion Therapeutics CYCN Stock Holding History

MFN Partners’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-169,460	Closed	-$437K	–	12
2024 Q3	$437K	Hold	169,460	–	–	0.01%	12
2024 Q2	$386K	Hold	169,460	–	–	0.01%	10
2024 Q1	$542K	Hold	169,460	–	–	0.02%	10
2023 Q4	$568K	Hold	169,460	–	–	0.02%	12
2023 Q3	$576K	Hold	169,460	–	–	0.02%	13
2023 Q2	$696K	Sell	169,460 -1	-0%	-$5	0.02%	14
2023 Q1	$1.47M	Hold	169,461	–	–	0.07%	15
2022 Q4	$2.22M	Hold	169,461	–	–	0.1%	16
2022 Q3	$2.92M	Hold	169,461	–	–	0.13%	17
2022 Q2	$1.86M	Hold	169,461	–	–	0.08%	16
2022 Q1	$3.76M	Hold	169,461	–	–	0.13%	20
2021 Q4	$5.83M	Hold	169,461	–	–	0.23%	14
2021 Q3	$10.4M	Hold	169,461	–	–	0.48%	14
2021 Q2	$13.2M	Buy	169,461 +48,077	+40%	+$3.01M	0.71%	13
2021 Q1	$6.77M	Hold	121,384	–	–	0.5%	15
2020 Q4	$7.43M	Hold	121,384	–	–	0.66%	14
2020 Q3	$14.8M	Hold	121,384	–	–	1.21%	14
2020 Q2	$14.3M	Hold	121,384	–	–	2%	9
2020 Q1	$6.43M	Buy	121,384 +46,990	+63%	+$3.35M	0.85%	13
2019 Q4	$4.05M	Hold	74,394	–	–	0.83%	10
2019 Q3	$18M	Hold	74,394	–	–	2.7%	10
2019 Q2	$17M	Buy	+74,394	New	+$21.1M	2.7%	11

Other funds holding CYCN

TCP

Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MFN Partners's CYCN Position: Q4 2024 in Review

MFN Partners sold out of Cyclerion Therapeutics (CYCN) in Q4 2024, closing a stake of 169,460 shares — an estimated $437K sold.

MFN Partners first reported a position in CYCN in Q2 2019 and held it in 22 quarters. The position peaked at $18M in Q3 2019. 19 funds tracked by Wall St. Rank hold CYCN as of Q4 2024.

MFN Partners reported no remaining Cyclerion Therapeutics position as of Q4 2024 after selling out during the quarter.
MFN Partners sold 169,460 Cyclerion Therapeutics shares in Q4 2024, an estimated $437K.
MFN Partners first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 22 quarters.
MFN Partners's Cyclerion Therapeutics position peaked at $18M in Q3 2019.
19 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2024.

Based on MFN Partners's 13F filing for Q4 2024, filed 12 Feb 2025.